THROMBOEMBOLISM
Clinical trials for THROMBOEMBOLISM explained in plain language.
Never miss a new study
Get alerted when new THROMBOEMBOLISM trials appear
Sign up with your email to follow new studies for THROMBOEMBOLISM, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Blood filtering shows promise for high lipoprotein(a) in dialysis patients
Disease control CompletedThis small completed study looked at a blood filtering procedure called double-filtration plasmapheresis (DFPP) in 5 kidney dialysis patients with very high levels of lipoprotein(a), a fatty substance linked to heart disease and blood clots. The goal was to see if DFPP could lowe…
Matched conditions: THROMBOEMBOLISM
Sponsor: Centre Hospitalier Régional Metz-Thionville • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC
-
Blood thinner after C-Section: small study tests safety and feasibility
Disease control CompletedThis pilot study tested whether giving the blood thinner enoxaparin after a C-section is feasible and safe. 64 women who had a C-section were randomly assigned to receive enoxaparin or no treatment for 14 days. The main goal was to see if enough women would join and complete the …
Matched conditions: THROMBOEMBOLISM
Phase: PHASE2 • Sponsor: University of Utah • Aim: Disease control
Last updated Jun 26, 2026 13:42 UTC
-
Hidden danger: study probes blood clot risk in cancer patients with COVID-19
Knowledge-focused CompletedThis study investigates how often cancer patients with COVID-19 develop dangerous blood clots (venous thromboembolism). Researchers will screen participants using ultrasound and blood tests to detect clots, whether or not they cause symptoms. The goal is to understand the true ra…
Matched conditions: THROMBOEMBOLISM
Phase: NA • Sponsor: Centre Antoine Lacassagne • Aim: Knowledge-focused
Last updated Jul 01, 2026 23:00 UTC
-
Which blood thinner costs less for cancer patients with clots? study investigates.
Knowledge-focused CompletedThis study looked at medical costs for cancer patients who had a blood clot (VTE) and were treated with either apixaban or low molecular weight heparin. Researchers analyzed insurance claims from over 7,300 patients to compare total healthcare costs, including hospital stays and …
Matched conditions: THROMBOEMBOLISM
Sponsor: Pfizer • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:55 UTC